Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

The French company’s randomised, non-comparative TEDOPaM study (NCT03806309) examined the efficacy of the company’s potential cancer vaccine in combination with Opdivo (nivolumab) followed by ...

Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...

Phase 2 trial results support further development of neoadjuvant nivolumab-based CIT and adaptive de-escalation of CRT in patients with locoregionally advanced HNSCC, according to researchers.

Use of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among ...

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR 1, expanding the eligibility of ...

An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

The firm completed enrollment of the first dose expansion cohort evaluating givastomig with immunotherapy and chemotherapy.

Inpatient ICI treatment produces poor outcomes across cancer types, according to the largest study of its kind.

I-Mab (IMAB) stock gains as an early-stage trial for its gastric cancer therapy givastomig advances in a faster than expected ...

Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus ...